FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995209087> ?p ?o ?g. }

• W2995209087 endingPage "2123" @default.
• W2995209087 startingPage "2111" @default.
• W2995209087 abstract "Preclinical data demonstrating androgen receptor (AR)-positive (AR+) triple-negative breast cancer (TNBC) cells are sensitive to AR antagonists, and PI3K inhibition catalyzed an investigator-initiated, multi-institutional phase Ib/II study TBCRC032. The trial investigated the safety and efficacy of the AR-antagonist enzalutamide alone or in combination with the PI3K inhibitor taselisib in patients with metastatic AR+ (≥10%) breast cancer.Phase Ib patients [estrogen receptor positive (ER+) or TNBC] with AR+ breast cancer received 160 mg enzalutamide in combination with taselisib to determine dose-limiting toxicities and the maximum tolerated dose (MTD). Phase II TNBC patients were randomized to receive either enzalutamide alone or in combination with 4 mg taselisib until disease progression. Primary endpoint was clinical benefit rate (CBR) at 16 weeks.The combination was tolerated, and the MTD was not reached. The adverse events were hyperglycemia and skin rash. Overall, CBR for evaluable patients receiving the combination was 35.7%, and median progression-free survival (PFS) was 3.4 months. Luminal AR (LAR) TNBC subtype patients trended toward better response compared with non-LAR (75.0% vs. 12.5%, P = 0.06), and increased PFS (4.6 vs. 2.0 months, P = 0.082). Genomic analyses revealed subtype-specific treatment response, and novel FGFR2 fusions and AR splice variants.The combination of enzalutamide and taselisib increased CBR in TNBC patients with AR+ tumors. Correlative analyses suggest AR protein expression alone is insufficient for identifying patients with AR-dependent tumors and knowledge of tumor LAR subtype and AR splice variants may identify patients more or less likely to benefit from AR antagonists." @default.
• W2995209087 created "2019-12-26" @default.
• W2995209087 creator A5005007467 @default.
• W2995209087 creator A5007261291 @default.
• W2995209087 creator A5011481394 @default.
• W2995209087 creator A5017831693 @default.
• W2995209087 creator A5026024346 @default.
• W2995209087 creator A5030367169 @default.
• W2995209087 creator A5031366322 @default.
• W2995209087 creator A5031736027 @default.
• W2995209087 creator A5032756469 @default.
• W2995209087 creator A5035798552 @default.
• W2995209087 creator A5037252693 @default.
• W2995209087 creator A5043946489 @default.
• W2995209087 creator A5053390874 @default.
• W2995209087 creator A5059563188 @default.
• W2995209087 creator A5062656698 @default.
• W2995209087 creator A5072853514 @default.
• W2995209087 creator A5073728088 @default.
• W2995209087 creator A5075889627 @default.
• W2995209087 date "2020-05-01" @default.
• W2995209087 modified "2023-10-14" @default.
• W2995209087 title "TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer" @default.
• W2995209087 cites W1919257374 @default.
• W2995209087 cites W1967761175 @default.
• W2995209087 cites W1984068087 @default.
• W2995209087 cites W1989938935 @default.
• W2995209087 cites W2005036868 @default.
• W2995209087 cites W2013147142 @default.
• W2995209087 cites W2023591758 @default.
• W2995209087 cites W2035921832 @default.
• W2995209087 cites W2063382533 @default.
• W2995209087 cites W2073100248 @default.
• W2995209087 cites W2080497992 @default.
• W2995209087 cites W2083926838 @default.
• W2995209087 cites W2088190208 @default.
• W2995209087 cites W2095249856 @default.
• W2995209087 cites W2095933146 @default.
• W2995209087 cites W2098804778 @default.
• W2995209087 cites W2110905563 @default.
• W2995209087 cites W2111393163 @default.
• W2995209087 cites W2113678263 @default.
• W2995209087 cites W2126144698 @default.
• W2995209087 cites W2128521034 @default.
• W2995209087 cites W2130189600 @default.
• W2995209087 cites W2132360977 @default.
• W2995209087 cites W2134539328 @default.
• W2995209087 cites W2135088554 @default.
• W2995209087 cites W2136879321 @default.
• W2995209087 cites W2138684882 @default.
• W2995209087 cites W2156274673 @default.
• W2995209087 cites W2166435610 @default.
• W2995209087 cites W2169353806 @default.
• W2995209087 cites W2169456326 @default.
• W2995209087 cites W2368819226 @default.
• W2995209087 cites W2404303850 @default.
• W2995209087 cites W2430731787 @default.
• W2995209087 cites W2560367415 @default.
• W2995209087 cites W2592811885 @default.
• W2995209087 cites W2599644610 @default.
• W2995209087 cites W2603390198 @default.
• W2995209087 cites W2625001374 @default.
• W2995209087 cites W2775307310 @default.
• W2995209087 cites W2784775153 @default.
• W2995209087 cites W2797726290 @default.
• W2995209087 cites W2804412041 @default.
• W2995209087 cites W2805124128 @default.
• W2995209087 cites W2805363969 @default.
• W2995209087 cites W2836525726 @default.
• W2995209087 cites W2897827524 @default.
• W2995209087 cites W2945564879 @default.
• W2995209087 cites W4211195653 @default.
• W2995209087 doi "https://doi.org/10.1158/1078-0432.ccr-19-2170" @default.
• W2995209087 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7196503" @default.
• W2995209087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31822498" @default.
• W2995209087 hasPublicationYear "2020" @default.
• W2995209087 type Work @default.
• W2995209087 sameAs 2995209087 @default.
• W2995209087 citedByCount "81" @default.
• W2995209087 countsByYear W29952090872020 @default.
• W2995209087 countsByYear W29952090872021 @default.
• W2995209087 countsByYear W29952090872022 @default.
• W2995209087 countsByYear W29952090872023 @default.
• W2995209087 crossrefType "journal-article" @default.
• W2995209087 hasAuthorship W2995209087A5005007467 @default.
• W2995209087 hasAuthorship W2995209087A5007261291 @default.
• W2995209087 hasAuthorship W2995209087A5011481394 @default.
• W2995209087 hasAuthorship W2995209087A5017831693 @default.
• W2995209087 hasAuthorship W2995209087A5026024346 @default.
• W2995209087 hasAuthorship W2995209087A5030367169 @default.
• W2995209087 hasAuthorship W2995209087A5031366322 @default.
• W2995209087 hasAuthorship W2995209087A5031736027 @default.
• W2995209087 hasAuthorship W2995209087A5032756469 @default.
• W2995209087 hasAuthorship W2995209087A5035798552 @default.
• W2995209087 hasAuthorship W2995209087A5037252693 @default.
• W2995209087 hasAuthorship W2995209087A5043946489 @default.
• W2995209087 hasAuthorship W2995209087A5053390874 @default.
• W2995209087 hasAuthorship W2995209087A5059563188 @default.

• next